ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor ...

BEIJING, June 02, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that updated data from the Company's novel BCL2 inhibitor mesutoclax in myelodysplastic...